Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Rhea-AI Summary
Mdxhealth (NASDAQ: MDXH) received a Nasdaq notice on June 30, 2026, stating its shares no longer meet the US$1.00 minimum bid price requirement for Nasdaq Capital Market listing.
The company has 180 days, until December 28, 2026, to regain compliance; operations remain unaffected, and options such as a reverse share split may be considered.
Positive
- 180-day compliance period granted until December 28, 2026
- Compliance achievable with ≥US$1.00 bid for 10 consecutive business days
- Current Nasdaq Capital Market listing status remains unchanged
- Company states business operations are not affected
- Potential eligibility for additional compliance period after December 28, 2026
Negative
- Non-compliance with Nasdaq US$1.00 minimum bid price rule
- 30 consecutive business days below US$1.00 triggered deficiency
- Risk of Nasdaq Capital Market delisting if compliance not regained
- May need actions such as a reverse share split to restore compliance
News Market Reaction – MDXH
In the Jul 6 session, MDXH gained 1.41%, reflecting a mild positive market reaction. Argus tracked a trough of -17.0% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 29 | Clinical publication | Positive | -6.3% | Peer‑reviewed publication of Oxford GPS-ProMPT data in European Urology Oncology. |
| May 13 | Q1 2026 results | Positive | -49.5% | Reported Q1 2026 revenue growth, guidance for 2026 and cash position update. |
| Apr 30 | Earnings call notice | Neutral | +1.0% | Announcement of date and time for Q1 2026 financial results release. |
| Mar 16 | Clinical data | Positive | -0.3% | EAU 2026 presentation of GPS-ProMPT data showing strong freedom‑from‑failure rates. |
| Feb 26 | FY 2025 earnings | Positive | -4.2% | Reported Q4 and full‑year 2025 revenue growth and reaffirmed 2026 guidance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent MDXH news with fundamentally positive content has more often been followed by negative share-price reactions.
Key Terms
minimum bid price regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received a notification letter (the “Notification Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), dated June 30, 2026, notifying the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure upon the receipt of a deficiency notification.
Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of US
The Notification Letter does not impact the Company’s listing on The Nasdaq Capital Market at this time. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided 180 calendar days, or until December 28, 2026, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the Company’s ordinary shares must have a closing bid price of at least US
The Company’s business operations are not affected by the receipt of the Notification Letter. The Company intends to monitor the closing bid price of its ordinary shares and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse share split of its outstanding ordinary shares, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules.
About mdxhealth
Mdxhealth is a leader in urology-focused precision diagnostics, providing actionable molecular information to personalize patient diagnosis and treatment. The Company’s tests, based on proprietary genomic, epigenomic, exosomal and other molecular technologies, assist physicians with the diagnosis and prognosis of prostate cancer and other urologic diseases. For more information, visit mdxhealth.com and follow us on social media at: x.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
For more information:
LifeSci Advisors (IR & PR)
John Fraunces, Managing Director
Tel: +1 917 355 2395
jfraunces@lifesciadvisors.com
Forward-Looking Statement: This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “potential,” “expect,” “will,” “goal,” “next,” “potential,” “aim,” “explore,” “forward,” “future,” and “believes” as well as similar expressions. Forward-looking statements contained in this release include, but are not limited to, statements regarding our intent to monitor our closing bid price and to consider options to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules,. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. Examples of forward-looking statements include, among others, statements we make regarding expected future operating results, product development efforts, our strategies, positioning, resources, capabilities and expectations for future events or performance. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, among others, the following: our ability to cure any deficiencies in compliance with the Bid Price Requirement or maintain compliance with other Nasdaq Listing Rules; our eligibility for additional compliance periods, if necessary, in which to seek to regain compliance with the Bid Price Requirement; our ability to ultimately obtain relief or extended periods to regain compliance from Nasdaq, if necessary, or to meet applicable Nasdaq requirements for any such relief or extension; and risks related to the substantial costs and diversion of personnel’s attention and resources due to these matters. Other important risks and uncertainties are described in the Risk Factors sections of our most recent Annual Report on Form 20-F and in our other reports filed with the Securities and Exchange Commission. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The mdxhealth logo, mdxhealth, Confirm mdx, Select mdx, Resolve mdx, Genomic Prostate Score, GPS mdx, GPS, Exosome Diagnostics, ExosomeDx, Exo mdx, ExoDx, ExoDx Prostate Intelliscore (EPI), and Monitor mdx are trademarks or registered trademarks of MDxHealth SA and its affiliates. The GPS mdx test was formerly known as and is frequently referenced in guidelines, coverage policies, reimbursement decisions, manuscripts and other literature as Oncotype DX Prostate, Oncotype DX GPS, Oncotype DX Genomic Prostate Score, and Oncotype Dx Prostate Cancer Assay, among others. The Oncotype DX trademark and all other trademarks and service marks, are the property of their respective owners.
